News
Context CEO Martin Lehr Named Finalist for EY Young Entrepreneur of The Year® in Greater Philadelphia
Context Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ONA-XR for the treatment of patients with progesterone receptor positive (PR+) ovarian cancer.
Context Therapeutics Receives FDA Fast Track Designation for ONA-XR for PR+ Ovarian Cancer
Context Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ONA-XR for the treatment of patients with progesterone receptor positive (PR+) ovarian cancer.
Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
Deepak Lala, Tasir Haque, Hannah Feinman, Jianghong Wu, Yuren Wang, Amy Dwyer, Thu Truong, and Carol Lange
San Antonio Breast Cancer Symposium I Poster P6-20-13 I Dec 4-8, 2018